Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.35 |
| ▸ | PPARG | P37231 | 4/20 | 0.34 |
| ▸ | PPARA | Q07869 | 1/20 | 0.34 |
| ▸ | DRD4 | P21917 | 7/20 | 0.34 |
| ▸ | DRD2 | P14416 | 2/20 | 0.34 |
| ▸ | DRD3 | P35462 | 2/20 | 0.34 |
| ▸ | REN | P00797 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | LTA4H | P09960 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9770964 | 0.90 | SLC5A2 (0.35) | HRH3PPARGPPARADRD4MEN1 | |
| SCHEMBL8880510 | 0.88 | HRH3 (0.34) | HRH3PPARGPPARADRD4DRD2 | |
| SCHEMBL9770796 | 0.86 | ADRB2 (0.37) | HRH3PPARGPPARADRD4MEN1 | |
| SCHEMBL9770835 | 0.84 | SLC2A1 (0.35) | HRH3PPARGPPARADRD4MEN1 | |
| SCHEMBL9770815 | 0.83 | HRH3 (0.42) | HRH3LTA4H | |
| SCHEMBL9770829 | 0.83 | ADRB2 (0.38) | HRH3PPARGPPARADRD4 | |
| SCHEMBL9770863 | 0.81 | ADRB2 (0.39) | HRH3PPARGPPARADRD4 | |
| SCHEMBL9770814 | 0.80 | GLA (0.40) | HRH3DRD4MEN1KMT2A | |
| SCHEMBL9770894 | 0.79 | AVPR1B (0.38) | HRH3MEN1KMT2A | |
| SCHEMBL9770892 | 0.78 | AVPR1B (0.38) | HRH3DRD4MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5026702-A | Enhances physical performance in animals, effective in lowering blood sugar, reducing body fat and lowering atherogenic lipoproteins | DR. KARL THOMAE, GMBH (DE) | 1991-06-25 | — | — | US | disclosed |
| EP-0334146-A1 | Morpholines and morpholine-N-oxides, medicines containing these compounds and process for their preparation | Dr. Karl Thomae GmbH (DE) | 1989-09-27 | — | — | EP | disclosed |